These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 12096400)
1. [Opportunities for the pharmaceutical industry at the Mexican Genomic Medicine Institute]. Jiménez-Sánchez G Gac Med Mex; 2002; 138(3):291-4. PubMed ID: 12096400 [No Abstract] [Full Text] [Related]
2. Developing a platform for genomic medicine in Mexico. Jimenez-Sanchez G Science; 2003 Apr; 300(5617):295-6. PubMed ID: 12690190 [TBL] [Abstract][Full Text] [Related]
3. Integrating genomics across drug discovery and development. Debouck C Toxicol Lett; 2009 Apr; 186(1):9-12. PubMed ID: 18930125 [TBL] [Abstract][Full Text] [Related]
4. Genomic medicine in Mexico: initial steps and the road ahead. Jimenez-Sanchez G; Silva-Zolezzi I; Hidalgo A; March S Genome Res; 2008 Aug; 18(8):1191-8. PubMed ID: 18676818 [TBL] [Abstract][Full Text] [Related]
5. Drug discovery and development in the age of molecular medicine. Vallance P; Levick M Clin Pharmacol Ther; 2007 Oct; 82(4):363-6. PubMed ID: 17851574 [TBL] [Abstract][Full Text] [Related]
7. Do pharmacogenetics, genomics and epigenetics hold promise for molecular therapeutics and health? Huber LA Curr Opin Mol Ther; 2010 Jun; 12(3):268-9. PubMed ID: 20556904 [TBL] [Abstract][Full Text] [Related]
8. [Drug discovery based on genome sciences and rational drug design]. Itai A Tanpakushitsu Kakusan Koso; 2001 Dec; 46(16 Suppl):2630-4. PubMed ID: 11802442 [No Abstract] [Full Text] [Related]
9. Academic-industrial partnerships in drug discovery in the age of genomics. Harris T; Papadopoulos S; Goldstein DB Trends Biotechnol; 2015 Jun; 33(6):320-2. PubMed ID: 25987446 [TBL] [Abstract][Full Text] [Related]
10. Pushing drugs: genomics and genetics, the pharmaceutical industry, and the law of negligence. Feldman HL Washburn Law J; 2003; 42(3):575-99. PubMed ID: 15115000 [No Abstract] [Full Text] [Related]
11. Genomics, public health and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN). Séguin B; Hardy BJ; Singer PA; Daar AS Nat Rev Genet; 2008 Oct; 9 Suppl 1():S5-9. PubMed ID: 18802419 [TBL] [Abstract][Full Text] [Related]
12. [Contributions of the National Institute of Nutrition to Mexican medicine]. Zubirán S Gac Med Mex; 1968 Feb; 98(2):131-8. PubMed ID: 5738262 [No Abstract] [Full Text] [Related]
15. SNP market view: opportunities, technologies, and products. Wypgant M Biotechniques; 2002 Jun; Suppl():78-80, 82, 84 passim. PubMed ID: 12083402 [No Abstract] [Full Text] [Related]
16. Personalized medicine: challenges in assessing and capturing value in the commercial environment. Ferrara J Expert Rev Mol Diagn; 2006 Mar; 6(2):129-31. PubMed ID: 16512770 [No Abstract] [Full Text] [Related]
17. The Institute for One World Health--a not-for-profit pharmaceutical company. Lundberg GD MedGenMed; 2005 Jan; 7(1):61. PubMed ID: 16369366 [No Abstract] [Full Text] [Related]